Editorial: Cytotoxic drugs and lupus nephritis

October 1973
British Medical Journal;10/6/1973, Vol. 4 Issue 5883, p6
Academic Journal
No abstract available.


Related Articles

  • Novel therapies in lupus nephritis associated with regulatory T cells. Qi Li; Bingxue Qi; Aosong Duan; Shiyue Zhao; Yixian Zhang; Xiaoxi Zhou; Wenpeng Dong; Yangwei Wang; Lining Miao // International Journal of Clinical & Experimental Medicine;2016, Vol. 9 Issue 11, p20702 

    Lupus nephritis is a major clinical manifestation of systemic lupus erythematosus. Corticosteroids and cytotoxic agents are standard of care for lupus nephritis treatment, but are associated with considerable morbidity and suboptimal outcomes. Recently, growing evidence confirmed that regulatory...

  • Management of lupus nephritis. BALOW, JAMES E.; BOUMPAS, DIMITRIOS T.; FESSLER, BARRI J.; AUSTIN III, HOWARD A. // Kidney International Supplement;Jan1996, Issue 53, pS-88 

    The article discusses the clinical management of lupus nephritis. Lupus nephritis is characterized by an increase in circulating immunoglobulins and autoantibodies. Immunoregulatory disturbances contribute to tissue destruction and result in impaired wound healing. The treatment for lupus...

  • Maintenance Therapy for Lupus Nephritis – Something Old, Something New. Balow, James E.; Austin, Howard A. // New England Journal of Medicine;3/4/2004, Vol. 350 Issue 10, p1044 

    This article looks at the various maintenance therapies for lupus nephritis. The diversity of pathogenic mechanisms in systemic lupus erythematosus (SLE) has shown that the disease arises from various environmental factors, hormonal milieus, genes, and other causes of immuno-regulatory...

  • Lupus Nephritis. Balow, James E.; Austin III, Howard A.; Tsokos, George C.; Antonovych, Tatiana T.; Steinberg, Alfred D.; Klippel, John H. // Annals of Internal Medicine;Jan87, Vol. 106 Issue 1, p79 

    Focuses on the immunopathogenesis of lupus nephritis. Summary of the immunologic and renal pathologic characteristics of systemic lupus erythematosus; Use of immunomodulating drugs; Clinical trials on management of lupus nephritis.

  • Mytcophenolate mofetil in lupus nephritis. Cross, J.; Jayne, D. // Lupus;2000, Vol. 9 Issue 9, p647 

    Editorial. Discusses the benefits of using mycophenolate mofetil (MMF) in the treatment of lupus nephritis. Role of MMF in chronic allograft nephropathy; Role of MMF for remission induction in severe biopsy proven lupus nephritis; Description of MMF.

  • Major lupus organ involvement: severe lupus nephritis. Avihingsanon, Y.; Hirankarn, N. // Lupus;Nov2010, Vol. 19 Issue 12, p1391 

    Lupus nephritis is a common and severe complication of systemic lupus erythematosus. A number of patients have nephritis as a presenting feature that, in its severe form, can shortly lead to end-stage renal disease and/or death. Renal flare usually occurs a few years after the first episode and...

  • The treatment of lupus nephritis: revisiting Galen. Lewis, Edmund J.; Lewis, E J // Annals of Internal Medicine;8/21/2001, Vol. 135 Issue 4, p296 

    Editorial. Discusses controversies concerning the therapeutic approach to patients with lupus nephritis. Prevalence of renal failure and death among patients with lupus nephritis despite continuing improvement in outcomes; Disagreement on the optimal approach to treatment of lupus nephritis;...

  • Cyclophosphamide in lupus nephritis. Houssiau, F. A. // Lupus;2005, Vol. 14 Issue 1, p53 

    Although not licensed for systemic lupus erythematosus (SLE), cyclophosphamide (CYC) has become over the last two decades the most widely prescribed cytotoxic drug for lupus nephritis (LN). A PubMed search using 'lupus nephritis and cyclophosphamide' as key words identifies not less than 454...

  • Safety of vaccination of patients with systemic lupus erythematosus. Abu-Shakra, M. // Lupus;Nov2009, Vol. 18 Issue 13, p1205 

    Live vaccines are not safe for immuno-compromised patients and should not be given to patients with systemic lupus erythematosus. In addition, all vaccines are not recommended for systemic lupus erythematosus patients when their disease is very active and mainly for patients with very active...

  • Drug News. DAVIS, JEANIE // Arthritis Today;Mar/Apr2012, Vol. 26 Issue 2, p56 

    The article offers drug-related news briefs such as the recommended dose of acetaminophen and the use of mycophenolate mofetil for treatment of lupus nephritis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics